本帖最后由 老马 于 2012-1-13 21:20 编辑
0 g" @* |+ G6 O. B& Q
- r! ^ E7 W$ R& ~9 X3 {$ x" s爱必妥和阿瓦斯丁的比较
! s" v3 [5 W1 t p- U5 Q" a% Y3 C
* a( E( q- O" uhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/& C% G6 C: e. j. q9 Y& k) r
9 ~7 M+ ~; L& f4 k2 s/ v
% Z X2 S7 R' M0 j8 K4 ?
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
2 G" d3 `! m! y- a==================================================
4 j( M3 @7 Z8 YOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)# Y9 j3 ~: }0 b: J3 s3 f# |
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.# y2 a, G1 M' E+ H0 X: K$ L
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
& D8 q* x6 P( T* }, I8 U
|